Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Carcinoma, Hepatocellular 18Neoplasms 13Neoplasm Metastasis 13Melanoma 13Esophageal Neoplasms 12Nasopharyngeal Carcinoma 10Head and Neck Neoplasms 9Esophageal Squamous Cell Carcinoma 9Colorectal Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Breast Neoplasms 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Recurrence 7Pancreatic Neoplasms 7Rectal Neoplasms 6Carcinoma, Renal Cell 6Biliary Tract Neoplasms 6Lung Neoplasms 5Small Cell Lung Carcinoma 4Sarcoma 4Ovarian Neoplasms 4Locally Advanced Rectal Cancer 4Colonic Neoplasms 4Advanced NSCLC 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Liver Neoplasms 3Leukemia, Myeloid, Acute 3

Interventions

pembrolizumab 5Oxaliplatin 3Nivolumab 3sintilimab 2Leucovorin 2Immune Checkpoint Inhibitors 2Fluorouracil 2Capecitabine 2Bevacizumab 2vicriviroc 1trifluridine tipiracil drug combination 1spartalizumab 1relatlimab 1regorafenib 1epacadostat 1dabrafenib 1copanlisib 1binimetinib 1atezolizumab 1Tiragolumab 1Irinotecan 1Fulvestrant 1E7046 1Cetuximab 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Spinocerebellar Degenerations × Immune Checkpoint Inhibitors × Clear all
NCT07551479 2026-04-24

TORCH-STAR

Fudan University

Phase 3 Not yet recruiting
612 enrolled

Spinocerebellar Degenerations

NCT06835179 2025-02-19

SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Not yet recruiting
28 enrolled
Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡